British Journal of Cancer - Issue - nature.com science feeds The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor. http://www.nature.com/bjc/current_issue/ Nature Publishing Group en Copyright © Cancer Research UK British Journal of Cancer 0007-0920 Copyright © Cancer Research UK permissions@nature.com British Journal of Cancer http://www.nature.com/aj/images/logos_b_o_w/bjc.gif http://www.nature.com/bjc/ The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy http://feeds.nature.com/~r/bjc/rss/current/~3/XvBWV_0AYcM/sj.bjc.6605349 The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy

British Journal of Cancer 101, 1807 (1 December 2009). doi:10.1038/sj.bjc.6605349

Authors: J Griggs & K Zinkewich-Peotti

]]> The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy J Griggs K Zinkewich-Peotti doi:10.1038/sj.bjc.6605349 British Journal of Cancer 101, 1807 (1 December 2009) 2009-11-24 British Journal of Cancer October 6, 2009 10.1038/sj.bjc.6605349 http://dx.doi.org/10.1038/sj.bjc.6605349 101 11 1807 1812 http://dx.doi.org/10.1038/sj.bjc.6605349 Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients http://feeds.nature.com/~r/bjc/rss/current/~3/VzKFQZAyxys/sj.bjc.6605413 Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients

British Journal of Cancer 101, 1813 (1 December 2009). doi:10.1038/sj.bjc.6605413

Authors: M Mego, U De Giorgi, K Broglio, S Dawood, V Valero, E Andreopoulou, B Handy, J M Reuben & M Cristofanilli

]]> Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients M Mego U De Giorgi K Broglio S Dawood V Valero E Andreopoulou B Handy J M Reuben M Cristofanilli doi:10.1038/sj.bjc.6605413 British Journal of Cancer 101, 1813 (1 December 2009) 2009-11-24 British Journal of Cancer November 3, 2009 10.1038/sj.bjc.6605413 http://dx.doi.org/10.1038/sj.bjc.6605413 101 11 1813 1816 http://dx.doi.org/10.1038/sj.bjc.6605413 CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients http://feeds.nature.com/~r/bjc/rss/current/~3/cHW0jBLvtKY/sj.bjc.6605428 CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

British Journal of Cancer 101, 1817 (1 December 2009). doi:10.1038/sj.bjc.6605428

Authors: H Jernström, E Bågeman, C Rose, P-E Jönsson & C Ingvar

]]> CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients H Jernström E Bågeman C Rose P-E Jönsson C Ingvar doi:10.1038/sj.bjc.6605428 British Journal of Cancer 101, 1817 (1 December 2009) 2009-11-24 British Journal of Cancer 10.1038/sj.bjc.6605428 http://dx.doi.org/10.1038/sj.bjc.6605428 101 11 1817 1823 http://dx.doi.org/10.1038/sj.bjc.6605428 CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer http://feeds.nature.com/~r/bjc/rss/current/~3/DElThmYzn2g/sj.bjc.6605423 CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer

British Journal of Cancer 101, 1824 (1 December 2009). doi:10.1038/sj.bjc.6605423

Authors: T van Agthoven, A M Sieuwerts, J Veldscholte, M E Meijer-van Gelder, M Smid, A Brinkman, A T den Dekker, I M Leroy, W F J van IJcken, S Sleijfer, J A Foekens & L C J Dorssers

]]> CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer T van Agthoven A M Sieuwerts J Veldscholte M E Meijer-van Gelder M Smid A Brinkman A T den Dekker I M Leroy W F J van IJcken S Sleijfer J A Foekens L C J Dorssers doi:10.1038/sj.bjc.6605423 British Journal of Cancer 101, 1824 (1 December 2009) 2009-11-24 British Journal of Cancer November 10, 2009 10.1038/sj.bjc.6605423 http://dx.doi.org/10.1038/sj.bjc.6605423 101 11 1824 1832 http://dx.doi.org/10.1038/sj.bjc.6605423 Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer http://feeds.nature.com/~r/bjc/rss/current/~3/N9B-tGulI1A/sj.bjc.6605422 Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

British Journal of Cancer 101, 1833 (1 December 2009). doi:10.1038/sj.bjc.6605422

Authors: E A M Heijnsdijk, A der Kinderen, E M Wever, G Draisma, M J Roobol & H J de Koning

]]> Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer E A M Heijnsdijk A der Kinderen E M Wever G Draisma M J Roobol H J de Koning doi:10.1038/sj.bjc.6605422 British Journal of Cancer 101, 1833 (1 December 2009) 2009-11-24 British Journal of Cancer November 10, 2009 10.1038/sj.bjc.6605422 http://dx.doi.org/10.1038/sj.bjc.6605422 101 11 1833 1838 http://dx.doi.org/10.1038/sj.bjc.6605422 Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000–2006 http://feeds.nature.com/~r/bjc/rss/current/~3/daCSMU2fLMw/sj.bjc.6605424 Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000–2006

British Journal of Cancer 101, 1839 (1 December 2009). doi:10.1038/sj.bjc.6605424

Authors: L Fairley, M Baker, J Whiteway, W Cross & D Forman

]]> Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000–2006 L Fairley M Baker J Whiteway W Cross D Forman doi:10.1038/sj.bjc.6605424 British Journal of Cancer 101, 1839 (1 December 2009) 2009-11-24 British Journal of Cancer November 10, 2009 10.1038/sj.bjc.6605424 http://dx.doi.org/10.1038/sj.bjc.6605424 101 11 1839 1845 http://dx.doi.org/10.1038/sj.bjc.6605424 Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials http://feeds.nature.com/~r/bjc/rss/current/~3/klPgklHVVO0/sj.bjc.6605377 Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

British Journal of Cancer 101, 1846 (1 December 2009). doi:10.1038/sj.bjc.6605377

Authors: A D Wagner, P Buechner-Steudel, M Moehler, H Schmalenberg, R Behrens, J Fahlke, A Wein, S Behl, O Kuss, G Kleber & W E Fleig

]]> Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials A D Wagner P Buechner-Steudel M Moehler H Schmalenberg R Behrens J Fahlke A Wein S Behl O Kuss G Kleber W E Fleig doi:10.1038/sj.bjc.6605377 British Journal of Cancer 101, 1846 (1 December 2009) 2009-11-24 British Journal of Cancer November 10, 2009 10.1038/sj.bjc.6605377 http://dx.doi.org/10.1038/sj.bjc.6605377 101 11 1846 1852 http://dx.doi.org/10.1038/sj.bjc.6605377 Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study http://feeds.nature.com/~r/bjc/rss/current/~3/v-uIgQxCspo/sj.bjc.6605420 Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study

British Journal of Cancer 101, 1853 (1 December 2009). doi:10.1038/sj.bjc.6605420

Authors: R Wilkowski, S Boeck, S Ostermaier, R Sauer, M Herbst, R Fietkau, M Flentje, S Miethe, H D Boettcher, T Scholten, C J Bruns, H G Rau, A Hinke & V Heinemann

]]> Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study R Wilkowski S Boeck S Ostermaier R Sauer M Herbst R Fietkau M Flentje S Miethe H D Boettcher T Scholten C J Bruns H G Rau A Hinke V Heinemann doi:10.1038/sj.bjc.6605420 British Journal of Cancer 101, 1853 (1 December 2009) 2009-11-24 British Journal of Cancer November 10, 2009 10.1038/sj.bjc.6605420 http://dx.doi.org/10.1038/sj.bjc.6605420 101 11 1853 1859 http://dx.doi.org/10.1038/sj.bjc.6605420 A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy http://feeds.nature.com/~r/bjc/rss/current/~3/_oO5DRedSDE/sj.bjc.6605425 A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy

British Journal of Cancer 101, 1860 (1 December 2009). doi:10.1038/sj.bjc.6605425

Authors: C P Lee, G S Payne, A Oregioni, R Ruddle, S Tan, F I Raynaud, D Eaton, M J Campbell, K Cross, G Halbert, M Tracy, J McNamara, B Seddon, M O Leach, P Workman & I Judson

]]> A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy C P Lee G S Payne A Oregioni R Ruddle S Tan F I Raynaud D Eaton M J Campbell K Cross G Halbert M Tracy J McNamara B Seddon M O Leach P Workman I Judson doi:10.1038/sj.bjc.6605425 British Journal of Cancer 101, 1860 (1 December 2009) 2009-11-24 British Journal of Cancer 10.1038/sj.bjc.6605425 http://dx.doi.org/10.1038/sj.bjc.6605425 101 11 1860 1868 http://dx.doi.org/10.1038/sj.bjc.6605425 Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact http://feeds.nature.com/~r/bjc/rss/current/~3/u0JJLEDo_nc/sj.bjc.6605438 Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact

British Journal of Cancer 101, 1869 (1 December 2009). doi:10.1038/sj.bjc.6605438

Authors: G Alì, L Boldrini, M Lucchi, A Picchi, M Dell'Omodarme, M C Prati, A Mussi, V Corsi & G Fontanini

]]> Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact G Alì L Boldrini M Lucchi A Picchi M Dell'Omodarme M C Prati A Mussi V Corsi G Fontanini doi:10.1038/sj.bjc.6605438 British Journal of Cancer 101, 1869 (1 December 2009) 2009-11-24 British Journal of Cancer 10.1038/sj.bjc.6605438 http://dx.doi.org/10.1038/sj.bjc.6605438 101 11 1869 1875 http://dx.doi.org/10.1038/sj.bjc.6605438 Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array http://feeds.nature.com/~r/bjc/rss/current/~3/6TKA6JgY-CQ/sj.bjc.6605409 Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

British Journal of Cancer 101, 1876 (1 December 2009). doi:10.1038/sj.bjc.6605409

Authors: J L Perez-Gracia, C Prior, F Guillén-Grima, V Segura, A Gonzalez, A Panizo, I Melero, E Grande-Pulido, A Gurpide, I Gil-Bazo & A Calvo

]]> Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array J L Perez-Gracia C Prior F Guillén-Grima V Segura A Gonzalez A Panizo I Melero E Grande-Pulido A Gurpide I Gil-Bazo A Calvo doi:10.1038/sj.bjc.6605409 British Journal of Cancer 101, 1876 (1 December 2009) 2009-11-24 British Journal of Cancer November 10, 2009 10.1038/sj.bjc.6605409 http://dx.doi.org/10.1038/sj.bjc.6605409 101 11 1876 1883 http://dx.doi.org/10.1038/sj.bjc.6605409 Increase in tumour permeability following TGF-β type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI http://feeds.nature.com/~r/bjc/rss/current/~3/3RSTMOsQnng/sj.bjc.6605367 Increase in tumour permeability following TGF-β type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI

British Journal of Cancer 101, 1884 (1 December 2009). doi:10.1038/sj.bjc.6605367

Authors: T Minowa, K Kawano, H Kuribayashi, K Shiraishi, T Sugino, Y Hattori, M Yokoyama & Y Maitani

]]> Increase in tumour permeability following TGF-β type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI T Minowa K Kawano H Kuribayashi K Shiraishi T Sugino Y Hattori M Yokoyama Y Maitani doi:10.1038/sj.bjc.6605367 British Journal of Cancer 101, 1884 (1 December 2009) 2009-11-24 British Journal of Cancer November 3, 2009 10.1038/sj.bjc.6605367 http://dx.doi.org/10.1038/sj.bjc.6605367 101 11 1884 1890 http://dx.doi.org/10.1038/sj.bjc.6605367 Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease http://feeds.nature.com/~r/bjc/rss/current/~3/tR13dxvDwYA/sj.bjc.6605379 Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease

British Journal of Cancer 101, 1891 (1 December 2009). doi:10.1038/sj.bjc.6605379

Authors: S Darby, T Murphy, H Thomas, C N Robson, H Y Leung, M E Mathers & V J Gnanapragasam

]]> Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease S Darby T Murphy H Thomas C N Robson H Y Leung M E Mathers V J Gnanapragasam doi:10.1038/sj.bjc.6605379 British Journal of Cancer 101, 1891 (1 December 2009) 2009-11-24 British Journal of Cancer November 3, 2009 10.1038/sj.bjc.6605379 http://dx.doi.org/10.1038/sj.bjc.6605379 101 11 1891 1899 http://dx.doi.org/10.1038/sj.bjc.6605379 Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro http://feeds.nature.com/~r/bjc/rss/current/~3/NuH0p7RA7lE/sj.bjc.6605419 Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro

British Journal of Cancer 101, 1900 (1 December 2009). doi:10.1038/sj.bjc.6605419

Authors: M Prencipe, P Fitzpatrick, S Gorman, M Mosetto, R Klinger, F Furlong, M Harrison, D O'Connor, I B Roninson, J O'Sullivan & A McCann

]]> Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro M Prencipe P Fitzpatrick S Gorman M Mosetto R Klinger F Furlong M Harrison D O'Connor I B Roninson J O'Sullivan A McCann doi:10.1038/sj.bjc.6605419 British Journal of Cancer 101, 1900 (1 December 2009) 2009-11-24 British Journal of Cancer 10.1038/sj.bjc.6605419 http://dx.doi.org/10.1038/sj.bjc.6605419 101 11 1900 1908 http://dx.doi.org/10.1038/sj.bjc.6605419 Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways http://feeds.nature.com/~r/bjc/rss/current/~3/lE2Sh1pcWFE/sj.bjc.6605405 Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways

British Journal of Cancer 101, 1909 (1 December 2009). doi:10.1038/sj.bjc.6605405

Authors: A-M Cleton-Jansen, J K Anninga, I H Briaire-de Bruijn, S Romeo, J Oosting, R M Egeler, H Gelderblom, A H M Taminiau & P C W Hogendoorn

]]> Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways A-M Cleton-Jansen J K Anninga I H Briaire-de Bruijn S Romeo J Oosting R M Egeler H Gelderblom A H M Taminiau P C W Hogendoorn doi:10.1038/sj.bjc.6605405 British Journal of Cancer 101, 1909 (1 December 2009) 2009-11-24 British Journal of Cancer November 3, 2009 10.1038/sj.bjc.6605405 http://dx.doi.org/10.1038/sj.bjc.6605405 101 11 1909 1918 http://dx.doi.org/10.1038/sj.bjc.6605405 Brain metastases admissions in Sweden between 1987 and 2006 http://feeds.nature.com/~r/bjc/rss/current/~3/xBIqJCxK0_U/sj.bjc.6605373 Brain metastases admissions in Sweden between 1987 and 2006

British Journal of Cancer 101, 1919 (1 December 2009). doi:10.1038/sj.bjc.6605373

Authors: K E Smedby, L Brandt, M L Bäcklund & P Blomqvist

]]> Brain metastases admissions in Sweden between 1987 and 2006 K E Smedby L Brandt M L Bäcklund P Blomqvist doi:10.1038/sj.bjc.6605373 British Journal of Cancer 101, 1919 (1 December 2009) 2009-11-24 British Journal of Cancer October 13, 2009 10.1038/sj.bjc.6605373 http://dx.doi.org/10.1038/sj.bjc.6605373 101 11 1919 1924 http://dx.doi.org/10.1038/sj.bjc.6605373 Assessment of breast cancer opportunistic screening by clinical–pathological indicators: a population-based study http://feeds.nature.com/~r/bjc/rss/current/~3/6h5qEhsKXDE/sj.bjc.6605378 Assessment of breast cancer opportunistic screening by clinical–pathological indicators: a population-based study

British Journal of Cancer 101, 1925 (1 December 2009). doi:10.1038/sj.bjc.6605378

Authors: A Bordoni, N M Probst-Hensch, L Mazzucchelli & A Spitale

]]> Assessment of breast cancer opportunistic screening by clinical–pathological indicators: a population-based study A Bordoni N M Probst-Hensch L Mazzucchelli A Spitale doi:10.1038/sj.bjc.6605378 British Journal of Cancer 101, 1925 (1 December 2009) 2009-11-24 British Journal of Cancer October 27, 2009 10.1038/sj.bjc.6605378 http://dx.doi.org/10.1038/sj.bjc.6605378 101 11 1925 1931 http://dx.doi.org/10.1038/sj.bjc.6605378 A prospective study of lifetime physical activity and prostate cancer incidence and mortality http://feeds.nature.com/~r/bjc/rss/current/~3/bRlPIASQqIU/sj.bjc.6605404 A prospective study of lifetime physical activity and prostate cancer incidence and mortality

British Journal of Cancer 101, 1932 (1 December 2009). doi:10.1038/sj.bjc.6605404

Authors: N Orsini, R Bellocco, M Bottai, M Pagano, S-O Andersson, J-E Johansson, E Giovannucci & A Wolk

]]> A prospective study of lifetime physical activity and prostate cancer incidence and mortality N Orsini R Bellocco M Bottai M Pagano S-O Andersson J-E Johansson E Giovannucci A Wolk doi:10.1038/sj.bjc.6605404 British Journal of Cancer 101, 1932 (1 December 2009) 2009-11-24 British Journal of Cancer October 27, 2009 10.1038/sj.bjc.6605404 http://dx.doi.org/10.1038/sj.bjc.6605404 101 11 1932 1938 http://dx.doi.org/10.1038/sj.bjc.6605404 Geographical and temporal distribution of cancer survival in teenagers and young adults in England http://feeds.nature.com/~r/bjc/rss/current/~3/FXJdDzbPIoc/sj.bjc.6605410 Geographical and temporal distribution of cancer survival in teenagers and young adults in England

British Journal of Cancer 101, 1939 (1 December 2009). doi:10.1038/sj.bjc.6605410

Authors: M Geraci, T O B Eden, R D Alston, A Moran, R S Arora & J M Birch

]]> Geographical and temporal distribution of cancer survival in teenagers and young adults in England M Geraci T O B Eden R D Alston A Moran R S Arora J M Birch doi:10.1038/sj.bjc.6605410 British Journal of Cancer 101, 1939 (1 December 2009) 2009-11-24 British Journal of Cancer November 3, 2009 10.1038/sj.bjc.6605410 http://dx.doi.org/10.1038/sj.bjc.6605410 101 11 1939 1945 http://dx.doi.org/10.1038/sj.bjc.6605410